Plus: Key Charter amendments—and it looks as if the DSA housing initiative is going to be hard to defeat. That's The Agenda ...
Incyte today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational ...
Spread the loveSo, you’ve got a burning passion, a cause that keeps you up at night, and a deep-seated desire to make the ...
Your read-it-later list is where articles go to die ...
There was an error while loading. Please reload this page.